Market capitalization | $356.76m |
Enterprise Value | $141.08m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.61 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-85.74m |
Free cash flow (TTM) Free cash flow | $-66.05m |
Cash position | $223.85m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
11 Analysts have issued a Cabaletta Bio Inc forecast:
11 Analysts have issued a Cabaletta Bio Inc forecast:
Dec '23 |
+/-
%
|
||
Net profit | -68 -68 |
28%
28%
|
|
Depreciation and amortization | 1.43 1.43 |
61%
61%
|
|
Share compensation | 11 11 |
64%
64%
|
|
Operating cash flow | -54 -54 |
15%
15%
|
|
Investments | 0.69 0.69 |
72%
72%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -54 -54 |
11%
11%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Nichtberger |
Employees | 103 |
Founded | 2017 |
Website | www.cabalettabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.